No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ALC240816C82500
- 3.60
- 0.000.00%
15min DelayTrading May 13 12:59 ET
0.00High0.00Low
0.00Open3.60Pre Close0 Volume127 Open Interest82.50Strike Price0.00Turnover27.82%IV-4.66%PremiumAug 16, 2024Expiry Date7.81Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9040Delta0.0256Gamma10.69Leverage Ratio-0.0325Theta0.0513Rho9.66Eff Leverage0.0407Vega
Intraday
- 5D
- Daily
News
Cooper Companies Raised to Buy at Jefferies on Valuation Disconnect
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17.
Jefferies Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $105
Jefferies analyst Michael Sarcone maintains $Alcon(ALC.US)$ with a buy rating, and adjusts the target price from $100 to $105.According to TipRanks data, the analyst has a success rate of 36.8% and
Jefferies Gives a Buy Rating to Alcon (ALC)
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
Morgan Stanley Cuts STAAR to Underweight, Cites Growth Expectations
Comments
$Alcon(ALC.US$ we broke out of that weekly resistance 89.43, lets see if we can continue to 90.66/90.94
$Alcon(ALC.US$
interesting setup. if we are able to break 89.43, we could see 90.66 / 90.44 and 91.88+. Reject 89.43 could take this down to 88.21 / 88.49 and maybe 86.98
interesting setup. if we are able to break 89.43, we could see 90.66 / 90.44 and 91.88+. Reject 89.43 could take this down to 88.21 / 88.49 and maybe 86.98
5
Baird advocates medtech companies such as Alcon, Stryker, and Cooper due to product and pricing strengths. Belief is strong in Alcon's 2024 margin possibilities, Stryker's premium pricing and predicted robust orthopedic demand, and projected revenue growth for Boston Scientific and Axonics.
Gapping up
$Rivian Automotive(RIVN.US$ +6% (The company reported a first-quarter loss that was narrower than expected. Rivian also said it's still on track to meet a 50,000-vehicle production target for 2023.)
$Celsius Holdings(CELH.US$ +11.1% (The company posted a strong earnings report. Celsius posted 40 cents in earnings per share for the first quarter, more than doubling the 19-cent consensus estimate of analysts polled by Str...
$Rivian Automotive(RIVN.US$ +6% (The company reported a first-quarter loss that was narrower than expected. Rivian also said it's still on track to meet a 50,000-vehicle production target for 2023.)
$Celsius Holdings(CELH.US$ +11.1% (The company posted a strong earnings report. Celsius posted 40 cents in earnings per share for the first quarter, more than doubling the 19-cent consensus estimate of analysts polled by Str...
11
Read more
103480872 : congrats
sentosa island : Alco is good